Back to Browse Journals » Drug Design, Development and Therapy » Volume 7

Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis

Authors Pitari GM

Published Date April 2013 Volume 2013:7 Pages 351—360

DOI http://dx.doi.org/10.2147/DDDT.S32252

Received 31 January 2013, Accepted 7 March 2013, Published 19 April 2013

Video abstract presented by Giovanni M Pitari

Views: 399

Giovanni M Pitari

Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA

Abstract: Agonists of the transmembrane intestinal receptor guanylyl cyclase C (GCC) have recently attracted interest as promising human therapeutics. Peptide ligands that can specifically induce GCC signaling in the intestine include endogenous hormones guanylin and uroguanylin, diarrheagenic bacterial enterotoxins (ST), and synthetic drugs linaclotide, plecanatide, and SP-333. These agonists bind to GCC at intestinal epithelial surfaces and activate the receptor’s intracellular catalytic domain, an event initiating discrete biological responses upon conversion of guanosine-5'-triphosphate to cyclic guanosine monophosphate. A principal action of GCC agonists in the colon is the promotion of mucosal homeostasis and its dependent barrier function. Herein, GCC agonists are being developed as new medications to treat inflammatory bowel diseases, pathological conditions characterized by mucosal barrier hyperpermeability, abnormal immune reactions, and chronic local inflammation. This review will present important concepts underlying the pharmacology and therapeutic utility of GCC agonists for patients with ulcerative colitis, one of the most prevalent inflammatory bowel disease disorders.

Keywords: inflammatory bowel disease, GCC agonists, cyclic GMP

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Phentermine and topiramate for the management of obesity: a review

Cosentino G, Conrad AO, Uwaifo GI

Drug Design, Development and Therapy 2013, 7:267-278

Published Date: 5 April 2013

Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics

Liu L, Ma Y, Wang RL, Xu WR, Wang SQ, Chou KC

Drug Design, Development and Therapy 2013, 7:279-288

Published Date: 8 April 2013

Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation

Gueler I, Mueller S, Helmschrott M, Oeing CU, Erbel C, Frankenstein L, Gleissner C, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA, Doesch AO

Drug Design, Development and Therapy 2013, 7:297-303

Published Date: 8 April 2013

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab

Armuzzi A, Pugliese D, Nardone OM, Guidi L

Drug Design, Development and Therapy 2013, 7:289-296

Published Date: 8 April 2013

Profile of certolizumab and its potential in the treatment of psoriatic arthritis

Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R

Drug Design, Development and Therapy 2013, 7:339-348

Published Date: 15 April 2013

Very rapid effect of pitavastatin on microvascular function in comparison to rosuvastatin: reactive hyperemia peripheral arterial tonometric study

Kono Y, Fukuda S, Shimada K, Nakanishi K, Otsuka K, Kubo T, Jissho S, Taguchi H, Yoshikawa J, Yoshiyama M

Drug Design, Development and Therapy 2013, 7:369-374

Published Date: 3 May 2013

Osteoporosis – a current view of pharmacological prevention and treatment

Das S, Crockett JC

Drug Design, Development and Therapy 2013, 7:435-448

Published Date: 31 May 2013